Online inquiry

IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9955MR)

This product GTTS-WQ9955MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets hly gene. The antibody can be applied in Staphylococcal infections research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2828033
UniProt ID P09616
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ9955MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13081MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-00547659
GTTS-WQ4890MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ9454MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IPH4102
GTTS-WQ6023MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ3763MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ11606MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MGD-006
GTTS-WQ11982MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MM-005
GTTS-WQ5385MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD4(178) PE40
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW